STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radiation boost could extend lives in aggressive liver cancer
Disease control Recruiting nowThis study is testing whether adding a precise, high-dose radiation treatment (SBRT) to standard immunotherapy drugs helps people with advanced liver cancer live longer. About 252 participants with liver cancer that has spread into major blood vessels will receive either immunoth…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Groundbreaking pill trial offers hope for tough liver cancers
Disease control Recruiting nowThis is the first human study of an experimental oral medication called AU409 for people with advanced liver cancers or other solid tumors that have spread to the liver. The main goal is to find the safest and most effective dose by testing it in a small group of patients whose c…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug duo targets genetic flaw in Tough-to-Treat liver cancer
Disease control Recruiting nowThis study is testing whether combining two drugs, sapanisertib and cabozantinib, works better than cabozantinib alone for people with advanced liver cancer that has a specific genetic mutation called β-catenin. The main goals are to find the safest dose of the combination and to…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Zapping tumors: wearable device tested with drugs for tough cancers
Disease control Recruiting nowThis early-stage trial is testing the safety of combining a wearable device that uses electric fields to disrupt cancer cells with different drug combinations. It is for adults with advanced cancers in the abdomen or chest that have spread and who have run out of standard treatme…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Mayo clinic tests 'Trained' immune cells to fight inoperable liver cancer
Disease control Recruiting nowThis study is testing a new combination treatment for advanced liver cancer that cannot be removed by surgery. Doctors take a patient's own immune cells, grow and train them in a lab to attack cancer, and then inject them directly into the tumor after radiation therapy. The goal …
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Radiation & immune drugs team up to fight spreading liver cancer
Disease control Recruiting nowThis study is testing if a short, intense course of radiation followed by immunotherapy drugs can help control advanced liver cancer that has spread. The goal is to see if this combination helps the body's immune system better recognize and attack the cancer. It is for adults who…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mary Feng, MD • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Old pain pill may help new cancer drugs fight tough liver tumors
Disease control Recruiting nowThis study is testing whether adding celecoxib, a common anti-inflammatory pain medication, can help two immunotherapy drugs work better against advanced liver cancer that has spread. The goal is to see if this combination can better control the cancer's growth and spread. Resear…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for rare liver cancer: triple therapy trial opens
Disease control Recruiting nowThis study is testing a combination of three drugs—nivolumab, fluorouracil, and interferon—for people with advanced fibrolamellar carcinoma, a rare liver cancer that cannot be removed by surgery. The main goals are to see if the treatment is safe and if it can shrink tumors or st…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Custom-Made vaccine aims to train immune system to fight advanced cancers
Disease control Recruiting nowThis study is testing a new, personalized vaccine designed to target the unique proteins on a patient's own cancer cells. It is being given alongside an existing immunotherapy drug (pembrolizumab) to see if the combination is safe and can help control advanced solid tumors that h…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New hope for liver cancer patients when first treatment stops working
Disease control Recruiting nowThis study is for people with advanced liver cancer that cannot be removed by surgery and has continued to grow despite their first treatment. Researchers want to see if continuing one of the original drugs (atezolizumab) alongside a new type of drug (cabozantinib or lenvatinib) …
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC